Home/Filings/4/0001104659-23-094815
4//SEC Filing

Javitt Jonathan C 4

Accession 0001104659-23-094815

CIK 0001719406other

Filed

Aug 23, 8:00 PM ET

Accepted

Aug 24, 12:14 PM ET

Size

7.8 KB

Accession

0001104659-23-094815

Insider Transaction Report

Form 4
Period: 2023-08-23
Javitt Jonathan C
DirectorChairman and Chief Scientist10% Owner
Transactions
  • Purchase

    Common Stock

    2023-08-23$0.33/sh+100,000$33,000446,332 total
Holdings
  • Common Stock

    (indirect: By the Jonathan Javitt Donor Advised Fund)
    300,000
  • Common Stock

    (indirect: By Trust)
    12,599,997
  • Common Stock

    (indirect: By Trust)
    1,422,000
Footnotes (3)
  • [F1]Held by the Jonathan Javitt Living Trust of which the reporting person is the trustee of such trust.
  • [F2]Held by the Javitt 2012 Irrevocable Dynasty Trust of which the reporting person is the grantor of such trust. The reporting person is not a trustee or beneficiary of the Trust, and no beneficiary of the Trust resides in the reporting person's household. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  • [F3]Held by the Jonathan Javitt Donor Advised Fund of which the reporting person is the primary advisor of such fund.

Issuer

NRX Pharmaceuticals, Inc.

CIK 0001719406

Entity typeother

Related Parties

1
  • filerCIK 0001303782

Filing Metadata

Form type
4
Filed
Aug 23, 8:00 PM ET
Accepted
Aug 24, 12:14 PM ET
Size
7.8 KB